Kainos Laboratories

Kainos Laboratories OCF Margin

Delisted

The Operating Cash Flow Margin of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 13.28 %. In the previous year, Operating Cash Flow Margin was 8.52 % — a change of 56.00% (higher).

OCF Margin

13.28 %

YoY

56.00%

Last updated:

Operating Cash Flow Margin of Kainos Laboratories is 2025 13.28 % . Operating Cash Flow Margin of Kainos Laboratories was 2024 8.52 % . It decreases by 56.00% higher compared to the previous year.

The Kainos Laboratories OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
7.70 JPY
Jan 1, 2019
9.11 JPY
Jan 1, 2020
14.71 JPY
Jan 1, 2021
13.89 JPY
Jan 1, 2022
13.10 JPY
Jan 1, 2023
11.06 JPY
Jan 1, 2024
8.52 JPY
Jan 1, 2025
13.28 JPY
The Kainos Laboratories OCF Margin history
YEAROCF MarginYoY
13.28 %+56.00%
8.52 %-23.01%
11.06 %-15.55%
13.10 %-5.69%
13.89 %-5.62%
14.71 %+61.54%
9.11 %+18.24%
7.70 %-2.97%
7.94 %+41.04%
5.63 %-21.66%
7.18 %+6.99%
6.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

Operating Cash Flow Margin of Kainos Laboratories is 13.28 % in 2025.

Operating Cash Flow Margin of Kainos Laboratories changed from 8.52 % to 13.28 %, representing a 56.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Kainos Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Kainos Laboratories

All Key Metrics — Kainos Laboratories